Home Clinical Topics FDA expands use of Xalkori

FDA expands use of Xalkori

On March 11, the Food and Drug Administration (FDA) approved Xalkori (crizotinib) to treat people with metastatic non-small cell lung cancer (NSCLC) whose tumors have an ROS-1 gene alteration. Xalkori is the first and only FDA approved treatment for patients with ROS-1 positive NSCLC. Read more

LEAVE A REPLY

Please enter your comment!
Please enter your name here